<?xml version="1.0" encoding="UTF-8"?>
<p>Considering the major impact of the proteasome in neurogenerative diseases, the development of proteasome activators is of great clinical interest. However, in face of the complexity of the proteasome, drugs able to stimulate its activity at multiple levels are predicted to ultimately have the highest clinical impact.</p>
